Pronoxis

Executive Summary

Pronoxis AB is a Swedish biotech company focused on preclinical development of small-molecule drugs targeting the Formyl Peptide Receptor 1 (FPR1) and NADPH oxidase 2 (NOX2) complex for chronic inflammatory, autoimmune, and infectious diseases. Founded in 2009, the company spent over a decade advancing its platform until 2024 when its core assets and intellectual property were transferred to the spin-off company Inicure AB. Following this transfer, Pronoxis has transitioned into a research management and collaboration entity, retaining an indirect interest in the former pipeline through its relationship with Inicure. While no longer an operating drug developer, Pronoxis may still benefit from future milestones achieved by Inicure or from potential licensing deals involving its remaining know-how. The company's current valuation and funding history are undisclosed, and it remains in a preclinical stage with no products on the market. Given the asset transfer and shift to a non-operating role, Pronoxis's near-term outlook is highly dependent on the success of its spin-off and the broader execution of its novel mechanism of action.

Upcoming Catalysts (preview)

• Q3 2026Inicure AB preclinical/clinical progress announcements30% success
• TBDPotential partnership or out-licensing of remaining IP20% success